research Endocrine Intervention for Transsexuals
Hormone treatment for transsexual individuals is effective but carries risks like thromboembolic events and mood changes, with most side effects being minor and reversible.
Search
for
Sort by
Research
30 / 521 results
research Cardiovascular Risk Factors and Events in Women with Androgen Excess
Women with androgen excess, especially those with PCOS, have a much higher risk of heart disease and stroke.
research Physiological and Biological Skin Changes in Pregnancy
Pregnancy causes skin changes like darkening, hair thickening, nail changes, and increased risk of skin growths, most of which usually resolve after birth.
research Complications of Rhytidectomy
Face-lifts can lead to complications like bleeding, nerve injury, skin death, hair loss, and rare infections, with careful surgery reducing risks.
research Hormonal Therapies for Acne
Hormonal treatments can improve acne, but they come with potential side effects and risks.
research Hormonal Treatment of Transgender Women with Oral Estradiol
Oral estradiol works for many transgender women but needs personalized dosing and monitoring.
research Immunological Aspects and Gender Bias During Respiratory Viral Infections Including Novel Coronavirus Disease-19 (COVID-19): A Scoping Review
Men are more likely to have severe respiratory viral infections like COVID-19 due to hormonal and genetic differences, while women generally have stronger immune responses.
research Management of Toxicities of Targeted Therapies
Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.
research Clinical Assessment of the Local Tolerance and Cosmetic Efficacy of a Topical Skin Care Formulation Used After 70% Glycolic Acid Facial Skin Rejuvenation Procedures in Healthy Female Subjects: A Randomized, Controlled, Evaluator-Blind Study
The moisturizing cream used after a chemical peel was well tolerated and effectively moisturized the skin.
research Characteristics and Outcomes of Patients on Tofacitinib for Alopecia Areata or Rheumatoid Arthritis: A Retrospective Cohort Study
Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.
research Safety Profile of Human Papilloma Virus Vaccines: An Analysis of the US Vaccine Adverse Event Reporting System from 2007 to 2017
HPV vaccines are generally safe but need further investigation for rare side effects.
research Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
research Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force Dermatology for Cancer Patients International Study
Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.
research Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database
People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.
research Gender-Affirming Hormone Therapy for Transgender Females
Hormone therapy for transgender females increases the risk of blood clots and requires careful dosing, monitoring, and lifelong management.
research Family Planning 2011: Better Use of Existing Methods, New Strategies, and More Informed Choices for Female Contraception
The conclusion is that there is a high demand for new contraceptives that provide both pregnancy prevention and protection against STIs, along with additional health benefits.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Integrated Safety Analysis of Baricitinib in Adults With Severe Alopecia Areata From Two Randomized Clinical Trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Drugs Affecting Blood Coagulation, Fibrinolysis, and Hemostasis
Some blood-thinning medications can increase the risk of bleeding, and certain factors like genetics and other health conditions affect their safety and effectiveness.
research Fulvestrant: A New Treatment Option for Advanced Breast Cancer - Tolerability Versus Existing Agents
Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
research Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study
Baricitinib is effective and safe for treating severe alopecia areata.
research Hormonal, Medical, and Nonsurgical Aspects of Gender Affirmation
The document concludes that gender-affirming treatments are essential for transgender individuals and outlines safe hormone therapy practices.
research Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm
CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
research Sex Hormones and Related Compounds, Including Hormonal Contraceptives
Exposure to certain sex hormones can increase health risks, while some hormone therapies may offer benefits for specific conditions.
research Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Cyclosporine A-Induced Intracranial Thrombotic Complications: Systematic Review and Case Report
Cyclosporine-A can cause serious blood clots in the brain, so patients need careful monitoring.
research Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population
Hormone therapy increases the risk of heart-related issues in transgender women and may affect heart health in transgender men.
research Efficacy and Safety of Baricitinib in Adults with Alopecia Areata: Phase 3 Results from a Randomized Controlled Trial (BRAVE-AA1)
Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.